521 related articles for article (PubMed ID: 32571559)
1. Impact of multidisciplinary team meetings on the management of venous thromboembolism. A clinical study of 142 cases.
Mauger C; Gouin I; Guéret P; Gac FN; Baillerie A; Lefeuvre C; Boutruche B; Bayard S; Jaquinandi V; Jégo P; Mahé G
J Med Vasc; 2020 Jul; 45(4):192-197. PubMed ID: 32571559
[TBL] [Abstract][Full Text] [Related]
2. Extended anticoagulation after venous thromboembolism: should it be done?
Fernandes CJ; Calderaro D; Piloto B; Hoette S; Jardim CVP; Souza R
Ther Adv Respir Dis; 2019; 13():1753466619878556. PubMed ID: 31558116
[TBL] [Abstract][Full Text] [Related]
3. How to treat venous thromboembolism (TVE) in cancer patients: ten years of multidisciplinary team meetings (MDTM) at Saint-Louis Hospital.
Crichi B; Sebuhyan M; Abdallah NA; Montlahuc C; Bonnet C; Villiers S; Maignan CL; Yannoutsos A; Farge D
J Med Vasc; 2020 Nov; 45(6S):6S24-6S30. PubMed ID: 33276940
[TBL] [Abstract][Full Text] [Related]
4. The optimal duration of anticoagulant therapy after unprovoked venous thromboembolism - still a challenging issue.
Elmi G; Di Pasquale G; Pesavento R
Vasa; 2017 Mar; 46(2):87-95. PubMed ID: 28102773
[TBL] [Abstract][Full Text] [Related]
5. Non-vitamin K antagonist oral anticoagulants (NOACs) for the management of venous thromboembolism.
Blann AD; Lip GY
Heart; 2016 Jun; 102(12):975-83. PubMed ID: 26984888
[No Abstract] [Full Text] [Related]
6. Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach.
Black SA; Cohen AT
Thromb Haemost; 2015 Oct; 114(4):660-9. PubMed ID: 26084864
[TBL] [Abstract][Full Text] [Related]
7. Considerations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant era.
Toth PP
Vasc Health Risk Manag; 2016; 12():23-34. PubMed ID: 26929637
[TBL] [Abstract][Full Text] [Related]
8. Management of cancer-associated venous thromboembolism - a case-based practical approach.
Voigtlaender M; Langer F
Vasa; 2018 Feb; 47(2):77-89. PubMed ID: 29325495
[TBL] [Abstract][Full Text] [Related]
9. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
Hillis C; Crowther MA
Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
[TBL] [Abstract][Full Text] [Related]
10. Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice. An Observational Study in Routine Clinical Practice.
den Exter PL; Hooijer J; van der Hulle T; van Oosten JP; Dekkers OM; Klok FA; Huisman MV
Thromb Haemost; 2017 Nov; 117(11):2163-2167. PubMed ID: 28981552
[TBL] [Abstract][Full Text] [Related]
11. Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests.
Prandoni P; Barbar S; Milan M; Campello E; Spiezia L; Piovella C; Pesavento R
Thromb Haemost; 2015 Jun; 113(6):1210-5. PubMed ID: 25119194
[TBL] [Abstract][Full Text] [Related]
12. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature.
Pillay B; Wootten AC; Crowe H; Corcoran N; Tran B; Bowden P; Crowe J; Costello AJ
Cancer Treat Rev; 2016 Jan; 42():56-72. PubMed ID: 26643552
[TBL] [Abstract][Full Text] [Related]
13. Association between anticoagulant treatment duration and risk of venous thromboembolism recurrence and bleeding in clinical practice.
Kaatz S; Fu AC; AbuDagga A; LaMori J; Bookhart BK; Damaraju CV; Tan H; Schein J; Nutescu E
Thromb Res; 2014 Oct; 134(4):807-13. PubMed ID: 25127013
[TBL] [Abstract][Full Text] [Related]
14. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
15. Use of New Oral Anticoagulants in the Treatment of Venous Thromboembolism and Thrombotic Prophylaxis.
Akin M; Schäfer A; Akin I; Widder J; Brehm M
Cardiovasc Hematol Disord Drug Targets; 2015; 15(2):92-6. PubMed ID: 26666324
[TBL] [Abstract][Full Text] [Related]
16. Great Debates in Vascular Medicine: Extended duration anticoagulation for unprovoked venous thromboembolism - Coming to consensus when the debate rages on.
Kanthi Y; Piazza G
Vasc Med; 2018 Aug; 23(4):384-387. PubMed ID: 29734862
[No Abstract] [Full Text] [Related]
17. Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer.
Hachey KJ; Hewes PD; Porter LP; Ridyard DG; Rosenkranz P; McAneny D; Fernando HC; Litle VR
J Thorac Cardiovasc Surg; 2016 Jan; 151(1):37-44.e1. PubMed ID: 26386868
[TBL] [Abstract][Full Text] [Related]
18. Compliance with a multidisciplinary team meeting's decision prior to bariatric surgery protects against major postoperative complications.
Rebibo L; Maréchal V; De Lameth I; Dhahri A; Escoffier I; Lalau JD; Regimbeau JM
Surg Obes Relat Dis; 2017 Sep; 13(9):1537-1543. PubMed ID: 28705572
[TBL] [Abstract][Full Text] [Related]
19. Edoxaban in venous thromboembolism and stroke prevention: an appraisal.
Proietti M; Lip GY
Vasc Health Risk Manag; 2016; 12():45-51. PubMed ID: 27013883
[TBL] [Abstract][Full Text] [Related]
20. Direct Oral Anticoagulants in the Treatment of Venous Thromboembolic Disease.
Salmerón Febres LM; Cuenca Manteca J
Ann Vasc Surg; 2017 Jul; 42():337-350. PubMed ID: 28390916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
